News
ZLDPF
46.95
NaN%
--
Zealand Pharma downgraded to Hold from Buy at Jefferies
TipRanks · 1d ago
Weekly Report: what happened at ZLDPF last week (0706-0710)?
Weekly Report · 2d ago
Novo Nordisk's Wegovy Pill Escalates Eli Lilly Rivalry
Seeking Alpha · 6d ago
Weekly Report: what happened at ZLDPF last week (0629-0703)?
Weekly Report · 07/06 09:24
Weekly Report: what happened at ZLDPF last week (0622-0626)?
Weekly Report · 06/29 09:23
Less Volume, More Premium: Post-Ozempic Economics Are Killing The Quantity Model
Benzinga · 06/22 11:15
Weekly Report: what happened at ZLDPF last week (0615-0619)?
Weekly Report · 06/22 09:26
Zealand Pharma downgraded to Hold from Buy at Berenberg
TipRanks · 06/17 08:25
Berenberg Bank downgrades Zealand Pharma (ZLDPF) to a Hold
TipRanks · 06/17 05:36
Weekly Report: what happened at ZLDPF last week (0608-0612)?
Weekly Report · 06/15 09:26
Roche and Zealand Advance Combo Obesity Drug Trial, Signaling New Momentum for ZLDPF
TipRanks · 06/12 16:31
Zealand Pharma tumbles 24% as weight-loss drug data sparks safety fears
Seeking Alpha · 06/08 10:27
Weekly Report: what happened at ZLDPF last week (0601-0605)?
Weekly Report · 06/08 09:24
Stocks Set to Open Higher Despite Israel-Iran Escalation, U.S. Inflation Data and SpaceX IPO Awaited
Barchart · 06/08 05:44
Zealand Pharma announces Boehringer’s phase III results of survodutide
TipRanks · 06/07 22:35
Zealand phase 2 data on petrelintide shows durable weight loss
Seeking Alpha · 06/05 21:42
Zealand Pharma presents additional data from ZUPREME-1 trial
TipRanks · 06/05 20:55
Zealand Pharma price target raised to DKK 300 from DKK 275 at Deutsche Bank
TipRanks · 06/04 16:18
Weekly Report: what happened at ZLDPF last week (0525-0529)?
Weekly Report · 06/01 09:26
Weekly Report: what happened at ZLDPF last week (0518-0522)?
Weekly Report · 05/25 09:27
More
Webull provides a variety of real-time ZLDPF stock news. You can receive the latest news about Zealand Pharma A/S through multiple platforms. This information may help you make smarter investment decisions.
About ZLDPF
Zealand Pharma A/S is a Denmark-based biotechnology company. The Company is focused on the discovery, design and development of peptide-based medicines for metabolic and gastrointestinal diseases and other rare disease areas with unmet medical needs. The Company's peptide-based product candidates includes clinical development, registration and, potentially, commercialization. Its pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome, or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for better diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The Company operates in Denmark and the USA and has a portfolio of medicines and product candidates, including collaborations with Boehringer Ingelheim.